Gritstone bio, Inc. (GRTS) Tops Q2 EPS by 4c

Gritstone bio, Inc. (NASDAQ: GRTS) reported Q2 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $1.96 million versus the consensus estimate of $2.51 million.

For earnings history and earnings-related data on Gritstone bio, Inc. (GRTS) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30